Structure Therapeutics (GPCR) Receivables (2025)
Structure Therapeutics (GPCR) posted quarterly Receivables of $200.0 million for Q4 2025.
Structure Therapeutics (GPCR) Receivables (2025) Analysis & Trends
Structure Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $200.0 million for Q4 2025.
- In Q4 2025, Receivables changed N/A year-over-year to $200.0 million; the TTM figure through Dec 2025 stood at $200.0 million (changed N/A YoY), while the FY2025 annual figure was $200.0 million, changed N/A from the prior year.
- Receivables for Q4 2025 stood at $200.0 million.
- The five-year high for Receivables was $200.0 million in Q4 2025, with the low at $200.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200.00 Mn |